drugset / Trial / NCT02124681

Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer

NCT02124681

Phase 1 Completed 34 enrolled University of Pittsburgh
RandomizedParallel-groupTriple-blindBasic science

Summary

Current options to treat insulin resistance in diabetes are fairly limited. For this reason, novel treatments would represent a major progress. The generic drug hydroxychloroquine (HCQ) has poorly understood effects on blood sugar metabolism. In this study, the investigators will examine the mechanisms by which this drug affects glucose metabolism and which cells are affected. Findings emanating from this project will help establish whether HCQ may be a viable treatment for disorders of glucose metabolism.

Timeline

Start
2014-04
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg Oral

Indications

No indication recorded.